December 2024 – Page 14

BioNTech Advances PD-L1/VEGF Bispecific Antibody with Encouraging Breast Cancer Trial Results

6 months ago talkbio0Tagged Antibodies, Bispecific, BioNTech, BNT327/PM8002, Clinical Trials, Combined Modality Therapy, Malignant neoplasm of breast, PD-L1/VEGF

BioNTech, PD-L1/VEGF Bispecific Antibody, BNT327/PM8002, Breast Cancer, Oncology Strategy, Clinical Trials, Combination Therapies

Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants

6 months ago talkbio0Tagged Advisory Committees, concerns, Infant, Moderna, Respiratory syncytial virus, RNA, Messenger, Safety, United States Food and Drug Administration, Vaccines

Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee

Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials

6 months ago talkbio0Tagged Antonio Breast Cancer Symposium, ER-positive, HER2-negative, Malignant neoplasm of breast, NAA50 gene, Olema Oncology, Oral SERD, palazestrant, Phase 3 Clinical Trials, SABCS

Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)

Cardiff Oncology’s Onvansertib Shows Promising Results in First-Line RAS-Mutated Metastatic Colorectal Cancer Trial

6 months ago talkbio0Tagged Cardiff Oncology, first-line, onvansertib, ORR, Phase 2, RAS, RAS-mutated

Cardiff Oncology, Onvansertib, RAS-mutated metastatic colorectal cancer, Phase 2 CRDF-004 trial, objective response rate (ORR), first-line treatment.

uniQure Secures FDA Agreement on Accelerated Approval Pathway for Huntington’s Disease Gene Therapy AMT-130

6 months ago talkbio0Tagged Accelerated, AMT-130, Approved, cUHDRS, gene therapy, Huntington 's disease, NEFL gene, NfL, Regenerative Medicine, RMAT, UniQure, United States Food and Drug Administration

uniQure, FDA, Accelerated Approval, Huntington’s Disease, Gene Therapy, AMT-130, cUHDRS, Neurofilament Light Chain (NfL), Regenerative Medicine Advanced Therapy (RMAT)

GSK and Relation Therapeutics Collaborate on Fibrosis and Osteoarthritis Research with AI-Driven Approach

6 months ago talkbio0Tagged Aortic Valve Insufficiency, Degenerative polyarthritis, Drug Discovery, Fibrosis, Machine Learning, Relative (related person), SmithKline Beecham

Relation Therapeutics, GSK, Fibrosis, Osteoarthritis, AI in drug discovery, Machine learning in biotech

2024 Biotech IPOs: Insights and Trends

6 months ago talkbio0Tagged 2024, biopharma sector, biotech, Capital, Health care facility, innovation, Investments, IPO, IPOs, public entity, trends qualifier, venture

Biotech IPOs, 2024 IPO trends, biopharma sector, initial public offerings, venture capital investment, healthcare innovation.

Eli Lilly Announces $15 Billion Share Buyback Plan and 15% Dividend Increase

6 months ago talkbio0Tagged dividend, Drug Industry, Eli, Eli Lilly, Increase, Market, Share Buyback

Eli Lilly, Share Buyback, Dividend Increase, Pharmaceutical Industry, Stock Market

Biotech Funding Boom: Tasca and Citryll Secure Significant Investments

6 months ago talkbio0Tagged Biotech Fundraising, Citryll, Fierce, Tasca, tracker, venture

Biotech fundraising, venture capital, Tasca, Citryll, Fierce Biotech Fundraising Tracker ’24

Belharra Biotech Cuts 21 Jobs Amid Industry-Wide Restructuring

6 months ago talkbio0Tagged Belharra, biotech, chemoproteomics, Industry, restructuring

Belharra Biotech, layoffs, chemoproteomics, biotech industry, restructuring